Tandem Diabetes Care (Nasdaq:TNDM) today shared its plans to submit a tubeless insulin pump to the FDA. On the company’s first-quarter earnings call, President and CEO John Sheridan outlined the plans for Mobi Tubeless, the company’s existing Mobi pump that utilizes a novel infusion set option for tubeless insulin delivery. Currently, Insulet offers the leading […]
MassDevice Earnings Roundup
Insulet sales grow 34% in Street-beating Q1 as company ups growth guidance
Insulet (Nasdaq:PODD) today reported first-quarter financial results that came in well ahead of the consensus forecast on Wall Street. Shares of PODD ticked up 5% to $175.79 before the market opened today. However, at midday, shares were down 8.2% at $153.78 apiece, potentially in response to scrutiny over U.S. trends and new patient starts. The […]
Embecta ‘disappointed’ with Q2 results that fell below expectations, cuts 2026 guidance
Embecta (Nasdaq:EMBC) today reported second-quarter financial results that fell shy of expectations on Wall Street. The BD Diabetes spinoff attributed shortcomings to increased competitive dynamics and softness in overall market volumes in the U.S. Its international business performed in line with expectations, however. Shares of EMBC fell 43% to $5.29 apiece before the market opened […]
Dexcom stock dips after hours despite Q1 beats, 15% sales growth
Dexcom (Nasdaq:DXCM) today posted first-quarter results that came in ahead of the Wall Street forecast. Shares of DXCM fell nearly 6% to $55.99 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) developer reported profits. of $199.5 million. That equals 51¢ per share on sales of $1.19 billion for the three months […]
Beta Bionics increases 2026 sales guidance on 57% Q1 growth
Beta Bionics (Nasdaq:BBNX) today reported first-quarter sales results that came in ahead of the forecast on Wall Street. For the full year, the company expects sales to range between $131 million and $136 million. It previously forecast between $130 million and $135 million. Shares of Beta Bionics fell 2% to $12.03 apiece after the market […]
Abbott CEO is bullish on CGM market despite analyst concerns
Abbott (NYSE:ABT) CEO Robert B. Ford remains optimistic about the company’s opportunity in the continuous glucose monitor (CGM) market. The company reported its first-quarter earnings today, which included $2 billion in FreeStyle Libre CGM sales, growing 7.5%. Abbott noted a delay in the renewal process related to an international tender, as well as an expected […]
Medtronic cuts 2026 guidance on private equity charge related to MiniMed approval
Medtronic (NYSE:MDT) said in an SEC filing that it lowered its full-year guidance after a one-time charge related to its MiniMed diabetes unit. Last week, MiniMed announced FDA clearance for the MiniMed Flex, a next-generation automated insulin delivery system. Clearance came “several months earlier than anticipated,” according to the filing, facilitating earlier commercialization. R&D for […]
Senseonics earns FDA IDE for next-gen Gemini CGM, posts Q4 revenue beat
Senseonics (NYSE:SENS) posted fourth-quarter results that proved mixed compared to Wall Street forecasts alongside a major pipeline announcement. Along with its fourth-quarter results, the company shared that it secured FDA investigational device exemption (IDE) for its self-powered, battery-enabled Gemini sensor. It enrolled the first patients in the IDE trial and expects to complete that in […]
ICU Medical resolves Smiths Medical warning letter, posts mixed Q4
ICU Medical (Nasdaq:ICUI) shares dipped slightly today on fourth-quarter results that were mixed compared to the consensus forecast. Shares of ICUI fell 1.25% to $149.74 apiece in early-morning trading today. The San Clemente, California-based infusion technology and critical care product provider reported losses of $15.7 million. That equals 64¢ per share on sales of $540.7 […]
Tandem stock rises on Q4 beats, new pay-as-you-go model
Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost today on fourth-quarter results that came in ahead of the consensus forecast. Shares of TNDM rose 11.5% to $20.65 apiece after the market closed today. The San Diego-based automated insulin delivery technology developer reported losses of 589 million. That equals 1¢ per share on sales of $290.4 […]
